Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPARγ-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 4, 2007, Pages 477-482

  Meshkani, Reza ^a   Taghikhani, Mohammad ^b   Larijani, Bagher ^a   Bahrami, Yadollah ^c   Khatami, Shohreh ^d   Khoshbin, Ehteram ^e   Ghaemi, Amir ^f   Sadeghi, Sedigheh ^d   Mirkhani, Fatemeh ^d   Molapour, Azam ^g   Adeli, Khosrow ^h  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

^e UNIVERSITY OF TEHRAN   (Iran)

^f GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g QAZVIN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Insulin resistance; Iranian population; Obesity; Peroxisome proliferator activated receptor 2 (PPAR 2); Pro12Ala; Type 2 diabetes

Indexed keywords

ALANINE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; IRAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ALANINE; BASE SEQUENCE; DIABETES MELLITUS, TYPE 2; DNA PRIMERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN RESISTANCE; IRAN; POLYMORPHISM, GENETIC; PPAR GAMMA; PROLINE;

EID: 34247355013     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.095     Document Type: Article

References (44)

1. Hamman R. Genetic and environmental determinants of non-insulin dependent diabetes mellitus (NIDDM). Diabetes Metab Rev 1992;8:287-338.
2. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002;90:3G-10G.
3. McCarthy MI, Hattersley AT. Molecular diagnostics in monogenic and multifactorial forms of type 2 diabetes. Expert Rev Mol Diagn 2001;1:403-12.
4. Tonntonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994;79:1147-56.
5. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. PPARg2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224-34.
6. Tontonoz P, Spiegelman BM. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor γ. Curr Opin Genet Dev 1995;5:571-6.
7. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14.
8. Weyer C, Funahashi T, Tanaka S. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
9. Kroder G, Bossenmaier B, Kellerer M. Tumor necrosis factor alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. J Clin Invest 1996;97:1471-7.
10. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-7.
11. Ek J, Andersen G, Urhammer SA, Hansen L, Carstensen B, Borch-Johnson K, et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) gene in relation to insulin sensitivity among glucose tolerant Caucasians. Diabetologia 2001;44:1170-6.
12. Hegele RA, Cao H, Harris SB, Zinman B, Hanley AJ, Anderson CM. Peroxisome proliferator-activated receptor-γ2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 2000;85:2014-9.
13. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, et al. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes 2001;50:886-90.
14. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000;271:212-6.
15. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPAR-gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
16. Vaccaro O, Mancini FP, Ruffa G, Sabatino L, Colantuoni V, Riccardi G. Pro12Ala mutation in the peroxisome proliferator-activated receptor gamma2 (PPARgamma2) and severe obesity: a case-control study. Int J Obes Rela Metab Disord 2000;24:1195-9.
17. Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor gamma2 gene with obesity in two Caucasian populations. Diabetes 1998;47:1806-8.
18. Yen CJ, Beamer BA, Negri C. Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: identification of a Pro12Ala PPARγ 2 missense mutation. Biochem Biophys Res Commun 1997;241:270-4.
19. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
20. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
21. Gauderman WJ. Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med 2002;21:35-50.
22. Ferrannini E, DeFronzo RA, Bonadonna RC. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992;15:318-68.
23. Goke B. Implications of blood glucose, insulin resistance and beta-cell function in impaired glucose tolerance. Diabetes Res Clin Pract 1998;40:S15-S20.
24. Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-2 Pro12Ala polymorphism. Diabetes 2002;51:2341-7.
25. Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, Shuldiner AR, et al. The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 2000;24:391-3.
26. Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor gamma2 is not associated with type 2 diabetes. Diabetes 1999;48:1466-8.
27. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, et al. Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000;24:195-9.
28. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferator activated, receptor gamma and diabetes mellitus. Biochem Biophys Res Commun 1999;254:450-3.
29. Radha V, Vimaleswaran KS, Babu HN, Abate N, Chandalia M, Satija P, et al. Role of genetic polymorphism of peroxisome proliferator-activated receptor-γ2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: evidence for heterogeneity. Diabetes Care 2006;29:1046-51.
30. Lindi VI, Uusitupa MI, Lindstrom J, Louheranta A, Eriksson JG, Valle TT, et al. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 2002;51:2581-6.
31. Sramkova D, Kunesova M, Hainer V, Hill M, Vcelak J, Bendlova B. Is a Pro12Ala polymorphism of the PPAR-gamma2 gene related to obesity and type 2 diabetes mellitus in the Czech population? Ann NY Acad Sci 2002;967:265-73.
32. Evans D, Heer J, Hagemann C, Wendt D, Wolf A, Beisiegel U, et al. Association between the P12A and c1431t polymorphisms in the peroxisome proliferators activated receptor gamma (PPAR gamma) gene and type 2 diabetes. Exp Clin Endocrinol Diabetes 2001:109:151-4.
33. Malecki TM, Frey J, Klupa T, Skupien J, Walus M, Mlynarski W, et al. The Pro12Ala polymorphism of PPARγ2 gene and susceptibility to type 2 diabetes in a Polish population. Diab Res Clin Pract 2003;62:105-11.
34. Meshkani R, Taghikhani M, Larijani B, Khatami S, Khoshbin E, Adeli K. The relationship between homeostasis model assessment and cardiovascular risk factors in Iranian subjects with normal fasting glucose and normal glucose tolerance. Clin Chim Acta 2006;371:169-75.
35. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, et al. The Pro12→Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001;50:891-4.
36. Linda Kao WH, Coresh J, Shuldiner AR, Boerwinkle E, Bray MS, Brancati FL. Pro12Ala of the peroxisome proliferator-activated receptor-γ2 gene is associated with lower serum insulin levels in nonobese African Americans. The Atherosclerosis Risk in Communities Study. Diabetes 2003;52:1568-72.
37. Wakil SM, Al-Rubeaan K, Imtiaz F, Carrol P, Rajab M, Al-Katari S, et al. The peroxisome proliferator-activated receptor-2 P12A polymorphism and type 2 diabetes in an Arab population. Diabetes Care 2006;29:171-2.
38. Fu M, Chen H, Li X, Li J, Wu B, Cheng L, et al. Association of Pro12Ala variant in peroxisome proliferator-activated receptor-gamma2 gene with type 2 diabetes mellitus. Zhonghoa Y Xue Yi Chuan Xue Za Zhi 2002;3:234-8.
39. Lei HH, Chen MH, Yang WS, Chiu MC, Chen MC, Tai TY, et al. Peroxisome proliferator-activated receptor gamma 2 Pro12Ala gene variant is strongly associated with larger body mass in the Taiwanese. Metabolism 2000;49:1267-70.
40. Mori Y, Kim-Motoyama H, Katakura T, Yasuda K, Kadowaki H, Beamer BA, et al. Effect of the Pro12Ala variant of the human peroxisome proliferator- activated receptor γ2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 1998;251:195-8.
41. Cole SA, Mitchell BD, Hsueh WC, Pineda P, Beamer BA, Shuldiner AR, et al. The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. Int J Obes Relat Metab Disord 2000;24:522-4.
42. Lindi V, Sivenius K, Niskanen L, Laakso M, Uusitupa MI. Effect of the Pro12Ala polymorphism of the PPAR-gamma2 gene on long-term weight change in Finnish nondiabetic subjects. Diabetologia 2001;44:925-6.
43. Buzzetti R, Petrone A, Ribaudo MC, Alemanno I, Zavarella S, Mein CA, et al. The common PPAR gamma2 Pro12Ala variant is associated with greater insulin sensitivity. Eur J Hum Genet 2004;12:1050-4.
44. Ghoussaini M, Meyre D, Lobbens S, Charpentier G, Clément K, Charles MA, et al. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med Genet 2005;6:1-8.